University of Leeds spinout adsilico secured the Series A funding round led by PXN Ventures, with existing investors Northern Gritstone and Parkwalk participating. The money will support further development of virtual heart models, expansion into neurovascular devices and workforce growth.
Trials of devices including stents and heart valves usually recruit only a few hundred people, limiting how well they represent potential recipients. Virtual Chimera builds digital versions of hearts and blood vessels using generative AI and anonymised clinical scans. Physics-based simulations then test device performance for patients with different medical conditions, body sizes, ethnicities, sexes and ages.
adsilico has already delivered projects for manufacturers of neurovascular devices and heart valves. Its technology helps manufacturers choose device sizes, identify higher-risk patients and refine clinical trial strategies. It provides additional evidence alongside existing testing methods and aims to identify potential problems earlier.